Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 27

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 27
---
 —

    Granted

    5,500

    75.00

    4.88

    Expired

    —

    —

    —

    Exercised

    —

    —

    —

    Outstanding June
    30, 2024

    5,500

    $
    75.00

    4.46

    Exercisable June
    30, 2024

    5,500

    $
    75.00

    4.46

    19 

A
summary of the status of the Company’s nonvested warrants as of June 30, 2025 and 2024, and changes during the three and
six months ended June 30, 2025 and 2024, is presented below:

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2024

    —

    $
    —

    Granted

    —

    —

    Vested

    —

    —

    Forfeited

    —

    —

    Non-vested at June 30, 2025

    —

    $
    —

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested at December 31,
    2023

    —

    $
    —

    Granted

    5,500

    75.00

    Vested

    (5,500
    )

    75.00

    Forfeited

    —

    —

    Non-vested at June 30, 2024

    —

    $
    —

The
total number of warrants granted during the three months ended June 30, 2025 and 2024 was 0 and 0,
respectively. The total number of warrants granted during the six months ended June 30, 2025 and 2024 was 0 and 5,500,
respectively. The exercise price for these warrants was $75.00 per share and there was an intrinsic value of $0.

The
Company recognized stock-based compensation expense related to warrant vesting amortization of $0 and $0 for the three and six
months ended June 30, 2025 and 2024, respectively.

RSUs